United Services Automobile Association Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

United Services Automobile Association acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 12,199 shares of the company’s stock, valued at approximately $295,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. SlateStone Wealth LLC increased its position in shares of Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the last quarter. Quest Partners LLC increased its position in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. Harbour Investments Inc. raised its stake in Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after buying an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC boosted its holdings in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Truist Financial upped their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Bank of America upped their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Leerink Partners lifted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Citigroup reissued a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a research report on Thursday, March 6th. Finally, Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $37.31.

Hims & Hers Health Trading Up 7.5 %

Shares of HIMS stock opened at $37.37 on Tuesday. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The stock has a market cap of $8.30 billion, a P/E ratio of 84.92 and a beta of 1.37. The stock has a 50 day moving average of $39.44 and a 200 day moving average of $29.05.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 36,460 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the transaction, the chief executive officer now directly owns 27,918 shares of the company’s stock, valued at $756,298.62. This represents a 56.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 998,244 shares of company stock worth $35,662,485. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.